Abstract
We evaluated the clinical efficacy and safety of meropenem (MEPM), a new carbapenem antibiotic. MEPM was administrated to 2 patients with bacteremia, 14 with pneumonia, 3 with mycoplasma pneumonia, 1 each with bacterial meningitis, atypical pneumonia, lung abscess, pharyngitis, DPB, chronic pulmonary emphysema, interstitial pneumonia, liver abscess and acute pyelonephritis. The patients received the drug intravenously for 8 to 32 days at a dose of 0.5-1.0 g/day. Clinical efficacy was excellent in 3 patients, good in 18, fair in 2 and unevaluable in 5. No side effects were observed. In five patients, GOT, G PT, ALP, γ-GTP, LAP, NAG and/or β2-MG were elevated mildly after administration of this drug.
